Format

Send to

Choose Destination
Hepatol Int. 2016 Sep;10(5):681-701. doi: 10.1007/s12072-016-9736-3. Epub 2016 May 26.

APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.

Author information

1
Yamanashi Prefectural Central Hospital, 1-1-1 Fujimi, Kofu-shi, Yamanashi, 400-8506, Japan. momata-tky@umin.ac.jp.
2
The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan. momata-tky@umin.ac.jp.
3
Graduate School of Medicine, Chiba University, Chiba, Japan.
4
Peking University People's Hospital, Peking University Hepatology Institute, Beijing, China.
5
Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
6
Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
7
GI/Liver Division, Department of Internal Medicine, University of Benha, Banha, Egypt.
8
Digestive Disease and GI Oncology Center, Medistra Hospital, University of Indonesia, Jakarta, Indonesia.
9
University Santo Tomas Hospital, Manila, Philippines.
10
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.
11
Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
12
Department of Medicine, Aga Khan University and Hospital, Stadium Road, Karachi, 74800, Pakistan.
13
Department of Gastroenterology, Ankara University School of Medicine, Ankara, Turkey.
14
Department of Hepatology, Bangabandhu Sheikh Mujib Medical University, Dhaka, 1000, Bangladesh.
15
Royal Prince Alfred Hospital, Centenary Institute, University of Sydney, Sydney, Australia.
16
University of Queensland, School of Medicine, Woolloongabba, QLD, 4102, Australia.
17
National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan.
18
The Institute of Translational Hepatology, Beijing 302 Hospital, Beijing, China.

Abstract

The Asian Pacific Association for the Study of the Liver (APASL) convened an international working party on "APASL consensus statements and recommendations for management of hepatitis C" in March 2015 to revise the "APASL consensus statements and management algorithms for hepatitis C virus infection" (Hepatol Int 6:409-435, 2012). The working party consisted of expert hepatologists from the Asian-Pacific region gathered at the Istanbul Congress Center, Istanbul, Turkey on 13 March 2015. New data were presented, discussed, and debated during the course of drafting a revision. Participants of the consensus meeting assessed the quality of the cited studies. The finalized recommendations for hepatitis C prevention, epidemiology, and laboratory testing are presented in this review.

PMID:
27229718
PMCID:
PMC5003900
DOI:
10.1007/s12072-016-9736-3
[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

Compliance with ethical standards All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki 1975, as revised in 2008 (5). Informed consent was obtained from all patients included in the study. This article does not contain any studies with animal subjects. Conflict of interest Alaaeldin Ibrahim, Cosmas Rinaldi Adithya Lesmana, Mamun Al-Mahtab, George K. K. Lau, Barjesh C. Sharma, Jose Sollano, Manoj Kumar, Ankur Jindal, A. Kadir Dokmeci, Geofferey W. McCaughan, Darrell H. G. Crawford, Jafri Wasim, and Shiv Kumar Sarin declare that they have no conflict of interest. Masao Omata received fees for being a speaker, consultant, and advisory board member for Bayer Co., Boehringer Ingelheim, Bristol-Myers Squibb, Otsuka, Astellas, Gilead Sciences, Chugai, Mitsubishi Tanabe, Kyorin, Merck Sharp & Dohme, Dainippon Sumitomo, Vertex Pharmaceuticals, Takeda, and Zeria. Tatsuo Kanda received lecture fees from Chugai Pharmaceutical, MSD, Tanabe-Mitsubishi, Daiichi-Sankyo, Bristol-Myers Squibb, Gilead Sciences, and AbbVie and a research grant from Chugai and MSD. Lai Wei has research grants from BMS and Roche and received consulting fees from Abbott, AbbVie, BMS, Gilead, and Novartis. Ming-Lung Yu is a consultant and advisory board member and has grant support from AbbVie, BMS, Gilead, Roche, MSD, and Abbott. Wang-Long Chuang received speaker fees from Gilead, BMS, MSD, Roche, and Novartis and is a member of the following advisory boards: Gilead, AbbVie, and Roche. Saeed S. Hamid has conference travel support from Gilead. Jia-Horng Kao has served as a consultant for AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Roche and has also served on speakers’ bureaus for Roche, Bristol-Myers Squibb, Gilead Sciences, and Novartis. Osamu Yokosuka has research grants from Chugai Pharmaceutical, Bayer, MSD, Daiichi-Sankyo, Tanabe-Mitsubishi, and Bristol-Myers Squibb and received speaking fees from Merck Sharp and Dohme, Kowa Souku, Sysmex, Chugai Pharmaceutical Co., GlaxoSmithKline, Bristol-Myers Squibb, Ajinomoto-Seiyaku, Bayer, Abbott, Given Imaging, Mitsubishi Tanabe Pharm, Taiho Yakuhin, Dainippon Sumitomo Pharm, and Igaku-Seibutsugaku Institute.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center